IN148482B
(fr)
|
1977-06-03 |
1981-03-07 |
Pfizer |
|
CA1114379A
(fr)
*
|
1977-11-03 |
1981-12-15 |
Pfizer Corporation |
Piperidino-phtalazines
|
US4370328A
(en)
|
1977-11-03 |
1983-01-25 |
Pfizer Inc. |
Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
|
US5001125A
(en)
*
|
1984-03-26 |
1991-03-19 |
Janssen Pharmaceutica N.V. |
Anti-virally active pyridazinamines
|
EP0174464B1
(fr)
*
|
1984-09-14 |
1990-01-03 |
ASTA Pharma AG |
Benzyl-phtalazinones substitués
|
US4868179A
(en)
*
|
1987-04-22 |
1989-09-19 |
Cohn Jay N |
Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
|
US5106973A
(en)
*
|
1987-11-23 |
1992-04-21 |
Janssen Pharmaceutica N.V. |
Pyridzainamine derivatives
|
US4963676A
(en)
*
|
1988-02-09 |
1990-10-16 |
Georgia State University Foundation, Inc. |
Di-substituted phthalazines
|
JO1645B1
(en)
*
|
1989-12-26 |
1991-11-27 |
شركة جانسين فارماسوتيكا ان. في |
Pyridazine compounds are antibacterial viruses
|
ES2068413T3
(es)
*
|
1990-03-30 |
1995-04-16 |
Mitsubishi Chem Ind |
Derivados de 4-fenilftalazina.
|
US5100893A
(en)
*
|
1990-04-18 |
1992-03-31 |
Janssen Pharmaceutica N.V. |
Antipicornaviral pyridazinamines
|
TW279162B
(fr)
*
|
1991-09-26 |
1996-06-21 |
Mitsubishi Chem Corp |
|
CH683965A5
(it)
*
|
1993-02-19 |
1994-06-30 |
Limad Marketing Exp & Imp |
Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
|
US5716956A
(en)
*
|
1995-06-07 |
1998-02-10 |
Bearsden Bearsden Bio, Inc. |
Dihydrophthalazine antagonists of excitatory amino acid receptors
|
ATE236134T1
(de)
*
|
1996-12-18 |
2003-04-15 |
Neurogen Corp |
Isoquinolinamin und phtalazinamin derivate, die reagieren mit crf rezeptoren
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
ATE329596T1
(de)
|
1999-03-30 |
2006-07-15 |
Novartis Pharma Gmbh |
Phthalazinderivate zur behandlung von entzündlicher erkrankungen
|
AR025068A1
(es)
*
|
1999-08-10 |
2002-11-06 |
Bayer Corp |
Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
|
US6689883B1
(en)
|
1999-09-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
CO5200835A1
(es)
*
|
1999-09-28 |
2002-09-27 |
Bayer Corp |
Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
|
DE19963607B4
(de)
*
|
1999-12-23 |
2005-12-15 |
Schering Ag |
Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
|
US7977333B2
(en)
*
|
2000-04-20 |
2011-07-12 |
Bayer Healthcare Llc |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
AR028782A1
(es)
*
|
2000-07-05 |
2003-05-21 |
Taisho Pharmaceutical Co Ltd |
Derivados heterociclicos tetrahidropiridino o piperidino
|
US6903101B1
(en)
|
2000-08-10 |
2005-06-07 |
Bayer Pharmaceuticals Corporation |
Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
|
GB0111078D0
(en)
*
|
2001-05-04 |
2001-06-27 |
Novartis Ag |
Organic compounds
|
US20030236259A1
(en)
*
|
2002-02-05 |
2003-12-25 |
Rolf Hohlweg |
Novel aryl- and heteroarylpiperazines
|
GB0223341D0
(en)
*
|
2002-10-08 |
2002-11-13 |
Groningen Acad Ziekenhuis |
Organic compounds
|
GB0310726D0
(en)
*
|
2003-05-09 |
2003-06-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
EP1709011B1
(fr)
*
|
2003-11-20 |
2015-07-29 |
Janssen Pharmaceutica NV |
2-quinolinones et 2 quinoxalinones a substitution 7-phenylalkyl comme inhibiteurs de poly(adp-ribose) polymerase
|
AU2004295058B9
(en)
|
2003-11-20 |
2011-06-30 |
Janssen Pharmaceutica N.V. |
6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
|
NZ547193A
(en)
*
|
2003-12-05 |
2010-03-26 |
Janssen Pharmaceutica Nv |
6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
AU2005260102A1
(en)
*
|
2004-05-08 |
2006-01-12 |
Novartis International Pharmaceutical Ltd. |
3-aryl-5,6-disubstituted pyridazines
|
US8014799B2
(en)
*
|
2004-06-02 |
2011-09-06 |
Ktfreetel Co., Ltd. |
System for providing application and management service and modifying user interface and method thereof
|
WO2006003147A1
(fr)
*
|
2004-06-30 |
2006-01-12 |
Janssen Pharmaceutica N.V. |
Derives de phtalazine utilises comme inhibiteurs de parp
|
ES2415771T3
(es)
|
2004-06-30 |
2013-07-26 |
Janssen Pharmaceutica N.V. |
Derivados de quinazolina como inhibidores de PARP
|
JP4969443B2
(ja)
|
2004-06-30 |
2012-07-04 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Parp阻害剤としてのキナゾリノン誘導体
|
US20060014829A1
(en)
*
|
2004-07-16 |
2006-01-19 |
Nitromed, Inc. |
Methods for reducing hospitalizations related to heart failure
|
US8758816B2
(en)
|
2004-11-24 |
2014-06-24 |
Meda Pharmaceuticals Inc. |
Compositions comprising azelastine and methods of use thereof
|
US20070020330A1
(en)
*
|
2004-11-24 |
2007-01-25 |
Medpointe Healthcare Inc. |
Compositions comprising azelastine and methods of use thereof
|
ES2704482T3
(es)
|
2004-11-24 |
2019-03-18 |
Meda Pharmaceuticals Inc |
Composiciones que comprenden azelastina y sus métodos de uso
|
RU2499795C2
(ru)
|
2005-07-04 |
2013-11-27 |
Хай Пойнт Фармасьютикалс, ЛЛС |
Антагонисты гистаминовых н3-рецепторов
|
EP1981868A2
(fr)
*
|
2006-01-27 |
2008-10-22 |
Pfizer Products Inc. |
Composes derives d aminophthalazine
|
EP1984010A4
(fr)
*
|
2006-02-17 |
2010-09-08 |
Nitromed Inc |
Procédés utilisant des composés d'hydralazine et du dinitrate d'isosorbide ou du mononitrate d'isosorbide
|
WO2007136626A1
(fr)
*
|
2006-05-16 |
2007-11-29 |
Nitromed, Inc. |
Formulations en doses solides de composés d'hydralazine
|
WO2007137968A1
(fr)
*
|
2006-05-29 |
2007-12-06 |
High Point Pharmaceuticals, Llc |
Benzodioxolylcyclopropylpipérazinylpyridazines
|
ES2381446T3
(es)
|
2007-03-08 |
2012-05-28 |
Janssen Pharmaceutica, N.V. |
Derivado de quinolinona como inhibidores de PARP y TANK
|
UA100684C2
(uk)
*
|
2007-03-15 |
2013-01-25 |
Новартіс Аг |
Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
|
EP2014656A3
(fr)
*
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
Nouveaux antagonistes d'hétéocycliques h3
|
PL2215075T3
(pl)
*
|
2007-10-26 |
2014-04-30 |
Janssen Pharmaceutica Nv |
Pochodne chinolinonu jako inhibitory PARP
|
US8889866B2
(en)
|
2008-03-27 |
2014-11-18 |
Janssen Pharmaceutica, Nv |
Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
|
ES2367760T3
(es)
*
|
2008-03-27 |
2011-11-08 |
Janssen Pharmaceutica, N.V. |
Derivados de quinazolinona como inhibidores de la polimerización de la tubulina.
|
NZ588001A
(en)
*
|
2008-04-29 |
2012-06-29 |
Lilly Co Eli |
Disubstituted phthalazine hedgehog pathway antagonists
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
DK2364185T3
(da)
*
|
2008-11-03 |
2013-06-03 |
Lilly Co Eli |
Disubstituerede phthalazin-hedgehog-pathway-antagonister
|
PL2358698T3
(pl)
|
2008-11-17 |
2013-01-31 |
Lilly Co Eli |
Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
|
CN102216292B
(zh)
*
|
2008-11-17 |
2014-08-13 |
伊莱利利公司 |
四取代的哒嗪hedgehog途径拮抗剂
|
WO2016123796A1
(fr)
*
|
2015-02-06 |
2016-08-11 |
Abbvie Inc. |
Phtalazines substituées
|
US10947241B2
(en)
*
|
2016-10-28 |
2021-03-16 |
Seoul National University Hospital |
Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
|
WO2022165173A1
(fr)
*
|
2021-01-28 |
2022-08-04 |
The Scripps Research Institute |
Composés et leur utilisation pour le traitement de troubles neurodégénératifs, dégénératifs et métaboliques
|
CN115433163A
(zh)
*
|
2021-06-05 |
2022-12-06 |
药捷安康(南京)科技股份有限公司 |
Nlrp3炎症小体抑制剂及其应用
|
CA3233482A1
(fr)
*
|
2021-09-30 |
2023-04-06 |
Origiant Pharmaceutical Co., Ltd |
Utilisation pharmaceutique et procede de preparation d'un derive d'heteroaryl-phtalazine substitue
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|